Kymriah, the first-ever FDA-approved CAR-T cell therapy, is currently available in 30 countries in one or more indications
Dr Lal PathLabs revenue contribution from west India to go up from 10% to 24% post-acquisition basis FY21
India reports 18 lakh stroke cases a year with 25 per cent patients below the age of 50
In collaboration with RAND Europe, the Vitality calculator predicts an individual's healthspan and future health risks
FUJIFILM will distribute iSWAB bio sampling technologies in Japan
Lifebit's accompanying suite of AI-powered end-to-end software solutions provide faster data insights, accelerate drug discovery pipelines, and improve clinical trials success
The CASPIAN Phase III trial in extensive-stage small-cell lung cancer is the longest survival follow-up ever reported for immunotherapy treatment in this setting
With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced breast cancer in the first-line (1L) setting
The approval will enable the treatment of patients in India living with Essential tremor, tremor-dominant Parkinson's Disease and neuropathic pain
Proceeds raised from the duathlon will go towards cancer treatment of children identified by the hospital
Subscribe To Our Newsletter & Stay Updated
